Background {#Sec1}
==========

One of the most common infectious diseases in the world, chronic hepatitis B is a serious public health problem in China \[[@CR1]\]. Pathogenesis of hepatitis B virus (HBV) is still not completely clear. Currently, the standard therapy for chronic hepatitis B is antiviral treatment with nucleoside analogs, including lamivudine, adefovir, entecavir, telbivudine, or tenofovir.

In October 2006, the L-nucleoside analog telbivudine at a dose of 600 mg/day was approved for HBV treatment. Compared to lamivudine, telbivudine showed a lower rate of drug resistance and higher rate of hepatitis B envelope antigen (HBeAg) seroconversion \[[@CR2]\]. However, a clinical trial revealed myopathy to be an adverse effect \[[@CR2]\]. Telbivudine therapy led to grade 3/4 creatine kinase (CK) elevation in 0.3 to 5% of patients \[[@CR3]\], as well as accelerated muscle toxicity in patients with pre-existing muscle damage \[[@CR4]\]. Telbivudine can also cause fatal rhabdomyolysis and lactic acidosis \[[@CR5], [@CR6]\].

Telbivudine-associated elevation of CK levels, myopathy, hyperlactatemia, and rhabdomyolysis have been frequently reported, whereas reports of multiple organ failure (MOF) are rare. Here, we describe a patient who was treated for 11 months with telbivudine for HBV and subsequently developed rhabdomyolysis, lactic acidosis, and MOF.

Case presentation {#Sec2}
=================

A 30-year-old Chinese man who had been HBeAg-positive for at least 10 years received telbivudine (Novartis Pharma AG, Basel, Switzerland) at a dosage of 600 mg once daily for 1 year before he presented to our hospital. He had no previous history of antiviral therapy. After 11 months of treatment, he complained of progressive pain and weakness in his lower extremities, poor appetite, nausea, and vomiting. Biochemical tests showed that his serum CK level had increased to 1000 U/L. Telbivudine was stopped immediately.

He was admitted to a ward with worsening symptoms. Laboratory tests were positive for hepatitis B surface antigen and HBeAg, but HBV deoxyribonucleic acid (DNA) was not detected. His serum CK level was elevated to 1220 U/L. Electromyography indicated slow nerve conduction velocity in both lower extremities. One week after admission, he developed shortness of breath, dyspnea, chest pain, malaise, and cold limbs with terminal cyanosis. The muscle strengths of his upper and lower extremities on the Medical Research Council scale were 2/5 and 1/5, respectively.

He was transferred to our intensive care unit, where he was found to have hypotension with a blood pressure of 82/43 mmHg. Oxygen saturation decreased to 80% despite nasal oxygen inhalation at a flow rate of 5 L/minute. Biochemical tests showed increased levels of alanine aminotransferase (ALT, 955 U/L), aspartate aminotransferase (AST, 1375 U/L), blood urea nitrogen (BUN, 14.9 mmol/L), serum CK (peak at 8050 U/L), and lactate dehydrogenase (LDH, 2040 U/L; Table [1](#Tab1){ref-type="table"}). He was put on continuous mechanical ventilation. Arterial blood gas analysis revealed lactic acidosis, with a partial pressure of oxygen (PO~2~) of 63 mmHg, partial pressure of carbon dioxide in arterial blood (PaCO~2~) of 24.7 mmHg, pH of 7.275, bicarbonate (HCO~3~ ^-^) of 11.6 mmol/L, and blood lactate level exceeding 20.0 mmol/L (upper limit of normal, 2.2 mmol/L).Table 1Major laboratory results according to days since hospital admissionParameter1 d8 d12 d14 d16 d18 d24 d28 d38 d49 d55 d62 d74 d84 d94 d105 dTB (umol/L)13.915.119.122.5--14.9--14.812.39.912.512.06.76.68.610.9ALT (U/L)25.080.0350.0955.0--166.0--73.048.032.034.025.011.015.014.017.0AST (U/L)74.0106.0216.01375.0217.0136.029.025.027.028.033.025.022.020.019.021.0ALB (g/L)38.032.335.433.7--31.8--38.841.037.838.238.737.638.538.941.0LDH (U/L)439.0438.0494.02040.0724.0693.0548.0368.0239.0--169.0----------CK (U/L)1220.01148.0416.03568.08050.02440.0124.073.056.054.084.0136.094.0189.095.0187.0CK-MB (U/L)17.022.013.636.943.326.313.412.39.69.210.610.710.010.010.112.1Lac (mmol/L)2.220.05.12.12.32.21.71.51.4--1.4--1.7--2.21.2WBC (× 10^9^/L)6.721.114.013.410.512.712.211.310.07.2--7.66.45.56.45.8RBC (× 10^12^/L)4.24.23.12.92.83.03.53.74.14.0--4.14.04.14.34.3PLT (× 10^9^/L)210.0329.048.048.046.082.0185.0182.0217.0187.0246.0236.0222.0197.0209.0BUN (mmol/L)3.614.911.610.59.05.54.35.14.62.11.91.22.52.42.02.0PT (seconds)--16.716.516.917.314.712.9------------------UMS (level)4.02.03.03.03.03.02.03.03.03.04.04.04.05.05.05.0LMS (level)3.01.01.01.01.01.01.02.03.03.03.03.03.04.04.04.0Normal ranges are given in parentheses as follows: *ALB* albumin (35--55 g/L), *ALT* alanine aminotransferase (5--45 U/L), *AST* aspartate aminotransferase (5--45 U/L), *BUN* blood urea nitrogen (1.7--7.1 mmol/L), *CK* creatine kinase (10--195 U/L), *d* days, *LDH* lactate dehydrogenase (80--285 U/L), *LMS* muscle strength of lower extremities (according to the Medical Research Council scale), - not detected, *CK-MB* cardiac creatinine phosphokinase isoenzyme (0--24 U/L), *Lac* lactate (0--2.2 mmol/L), *PLT* platelet (100--300 × 10^9^/L), *PT* prothrombin time (10--14.5 seconds), *RBC* red blood cell (4.0--5.5 × 10^12^/L), *TB* total bilirubin (1.7--22.5 μmol/L), *UMS* muscle strength of upper extremities (according to the Medical Research Council scale), *WBC* white blood cell (4.0--10.0 × 10^9^/L)

Continuous renal replacement therapy (CRRT) was maintained for 10 days, and methylprednisolone was initiated at 80 mg twice daily. These treatments led to improvements in his chest pain, dyspnea, and laboratory parameters (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}), but did not resolve his poor muscle strength. A biopsy of his left gastrocnemius muscle showed multiple nerve root inflammation and polymyositis with multiple degenerating atrophic myofibers and numerous necrotic myofibers infiltrated with macrophages (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Patient's serum lactate and creatine kinase levels during his stay in our intensive care unit Fig. 2Muscle biopsy from left gastrocnemius muscle. Hematoxylin and eosin-stained paraffin section of muscle biopsy. Multiple degenerating atrophic myofibers (*arrow*) and numerous necrotic myofibers infiltrated by macrophages were observed, indicating multiple nerve root inflammation and polymyositis (original magnification, ×200)

He was transferred from our intensive care unit to our infectious disease ward. His HBV DNA was elevated at 8.48 × 10^4^ IU/ml. Antiviral treatment with adefovir dipivoxil (10 mg once daily) was started. To improve muscle strength, he received simultaneous hyperbaric oxygen (HBO) therapy for approximately 40 days, as well as physical therapy and rehabilitation (PTR; including neuromuscular electrical stimulation therapy, comprehensive paraplegic limb training, electro-acupuncture treatment, and infrared therapy) for approximately 70 days. His muscle strength gradually improved, and his serum ALT, AST, CK, and LDH levels returned to normal. He was then discharged. Six months after discharge, his muscle strength was within the normal range. He resumed his work as a taxi driver 1 year after discharge. Relationships between primary treatment, CK levels, and muscle strength are shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 3Relationship between primary treatment, creatine kinase level, and muscle strength. *CK* creatine kinase, *CRRT* continuous renal replacement therapy (for 8 days), *D 1* Day 1, *GC* glucocorticoid therapy (including methylprednisolone, dexamethasone, and prednisone, for 44 days), *HBO* hyperbaric oxygen therapy (for 40 days), *LMS* muscle strength of lower extremities (according to the Medical Research Council scale), *PTR* physical therapy and rehabilitation (for 70 days)

Discussion {#Sec3}
==========

A new nucleoside analog for treatment of chronic hepatitis B, telbivudine inhibits synthesis of second-strand DNA through competing with the natural substrate of DNA polymerase (reverse transcriptase) \[[@CR7], [@CR8]\]. In one phase II clinical trial, telbivudine monotherapy reduced serum HBV DNA and ALT levels more rapidly than lamivudine monotherapy \[[@CR9]\]. Telbivudine is currently regarded as an efficacious, well-tolerated, and safe drug for HBV treatment \[[@CR10]\]. Despite these advantages, there have been frequent reports of adverse effects, including elevation of CK levels, myopathy, and neuropathy, associated with telbivudine treatment, particularly when combined with pegylated interferon \[[@CR11]\]. The GLOBE study showed that telbivudine was more frequently associated with asymptomatic hyper-CK-emia compared to lamivudine (12.9 versus 4.1%) \[[@CR2]\]. Among patients treated with telbivudine, 12 to 14% reported fatigue and malaise, 9% reported asymptomatic hyper-CK-emia, and 0.5% reported myopathy during treatment \[[@CR12]\].

Male sex, younger age, and HBeAg negativity were independent predictors of elevated CK levels in patients receiving telbivudine treatment in China \[[@CR3]\]. Recently, Chen *et al*. found that male sex and lower baseline estimated glomerular filtration rate were significant risk factors for elevation of CK levels during telbivudine treatment \[[@CR13]\]. In our patient, the CK level was markedly elevated (peak at 8050 U/L). Male sex may have been associated with prolonged exercise or acceleration of pre-existing muscle damage, a phenomenon that was reported previously \[[@CR4]\].

Several studies reported telbivudine-related myopathy and neuropathy, but these side effects were typically mild and reversible \[[@CR14]--[@CR17]\]. To date, reports of telbivudine-induced severe side effects, such as rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF, have been very rare. Jin *et al*. described a 36-year-old man who developed severe refractory lactic acidosis during telbivudine monotherapy. He fully recovered after 16 weeks of hemodialysis and glucocorticosteroid treatment \[[@CR6]\]. Wang *et al*. described a patient who developed hyperlactatemia during telbivudine treatment and was successfully treated with continuous venovenous hemodiafiltration \[[@CR18]\]. However, another patient with telbivudine-induced rhabdomyolysis developed acute renal failure and metabolic acidosis by day 18 after admission and, despite hemofiltration, died within 24 hours of developing these symptoms \[[@CR5]\]. Table [2](#Tab2){ref-type="table"} lists characteristics of previously reported patients who developed severe adverse effects during telbivudine treatment. As these conditions are potentially fatal, immediate hemodialysis and glucocorticosteroid therapy are indicated.Table 2Literature review of patients who developed severe adverse events during telbivudine treatmentPatient numberAge (years)Adverse effectLiver conditionTx time (months)Peak CK (U/L)Peak lactate (mmol/L)PrognosisReference127MyopathyCHB33243--Resolved\[[@CR4]\]267MyopathyCHB204775--Resolved\[[@CR14]\]325MyopathyCHB61614--Resolved\[[@CR15]\]428MyopathyCHB9788--Resolved\[[@CR16]\]525MyopathyCHB132992--Resolved\[[@CR16]\]668MyopathyCHB2237--Resolved\[[@CR17]\]735Rhabdomyolysis, lactic acidosisCHB113683\> 12.0Resolved\[[@CR6]\]826lactic acidosisCHB12415111.3Resolved\[[@CR18]\]930Rhabdomyolysis, lactic acidosis, organ failureCHB118050\> 20.0ResolvedThis paper1048Rhabdomyolysis, metabolic acidosis, organ failureCirrhosis93246--Death\[[@CR5]\]*CHB* chronic hepatitis B, *CK* creatine kinase, *Tx* treatment, lactate mmol/L × 9.608 = mg/dL

The risk factors for telbivudine-induced rhabdomyolysis, hyperlactatemia, lactic acidosis, or MOF are still unclear. A previous study found telbivudine appears to cause accelerated muscle toxicity if given to patients who already have muscle damage \[[@CR4]\]. Another research found that in liver transplant recipients, telbivudine-induced polyneuropathy/myopathy maybe due to diabetes \[[@CR19]\]. When it comes to lactic acidosis or hyperlactatemia caused by telbivudine, Jin *et al*. found that a case with telbivudine-induced lactic acidosis had a history of hypokalemic periodic paralysis, but the relationship between the pre-existence of myopathy and telbivudine treatment was uncertain \[[@CR6]\]. However, like the case of another previous study, our patient also had no heavy exercise or heavy drinking, and had no history of diabetes mellitus \[[@CR18]\]. Thus the risk factors for telbivudine-induced lactic acidosis or MOF are still ambiguous and need to be further explored. The case in this study developed severe telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF; the reason maybe that his elevated CK levels and rhabdomyolysis were not discovered in a timely manner because he received no regular reexamination. Although telbivudine was stopped, the rhabdomyolysis continue progressed and developed to lactic acidosis and MOF. So during the telbivudine treatment for HBV, except for detecting the possible risk factors associated with telbivudine-induced rhabdomyolysis or lactic acidosis, monitoring for muscular abnormalities, CK levels, and rhabdomyolysis is also very important for these cases.

Mechanisms underlying telbivudine-induced myopathy and lactic acidosis remain unclear. Whereas some studies showed that telbivudine may cause mitochondrial toxicity and dysfunction, which might lead to myopathy and lactic acidosis \[[@CR20]\], *in vitro* studies indicated no effect of the drug on lactic acid production, mitochondrial DNA content, or morphology \[[@CR21]\]. Recently, Hernández-Laín *et al*. identified a novel *RRM2B* gene variant associated with telbivudine-induced mitochondrial myopathy \[[@CR22]\]. Therefore, the mechanism remains to be elucidated.

In this report, we describe the case of 30-year-old man with telbivudine-induced severe side effects, including rhabdomyolysis, lactic acidosis, and MOF. His condition deteriorated rapidly after admission, with shortness of breath, muscle weakness, hypotension, hypoxia, and elevated CK levels within 1 week. Several reasons may account for the severe effects. Physicians may not have paid enough attention to the elevation of CK levels and myopathy during gastroenterology follow up. Underlying causes of his worsening condition were not immediately confirmed. CRRT and immunosuppressive therapy may not have been started as early as possible. Despite delays in diagnosis and treatment, our patient improved after CRRT and methylprednisolone therapy, which played key roles in the telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF.

The role of glucocorticoid in the treatment of telbivudine-induced rhabdomyolysis, lactic acidosis, and MOF are unclear. In this study, we found our patient's elevated lactate level in his blood and rhabdomyolysis improved significantly after CRRT and methylprednisolone therapy. But in another study, a patient with telbivudine-induced rhabdomyolysis only received hemofiltration therapy, the patient did not receive glucocorticoid therapy, and died within 24 hours \[[@CR5]\]. Thus, the CRRT and glucocorticoid therapy may play key roles in stabilizing telbivudine-induced severe rhabdomyolysis, lactic acidosis, and MOF. Another study found that low-dose glucocorticoid for a short period of time may help to return the blood lactate level to normal, and the current study also indicated that CRRT combined with methylprednisolone therapy help to reduce the blood lactate level to normal.

However, we found that low-dose glucocorticoid therapy could not improve the poor muscle strength of our patient \[[@CR6]\]. HBO therapy, which is very helpful in optic neuritis \[[@CR23]\], can be used to treat myositis \[[@CR24]\], although there have been no reports of HBO therapy for telbivudine-induced myositis or neuritis. A biopsy confirmed multiple nerve root inflammation and polymyositis in our patient, who subsequently received HBO therapy for more than 1 month and PTR for more than 2 months. Our patient gradually recovered, indicating that these interventions may be helpful in the treatment of telbivudine-induced myositis and neuritis. To the best of our knowledge, the patient in this study was the first case which experienced myopathy, rhabdomyolysis, lactic acidosis, shock, and MOF during telbivudine treatment and be treated successfully.

Conclusions {#Sec4}
===========

Telbivudine can cause severe side effects, including myositis, neuritis, rhabdomyolysis, lactic acidosis, and even MOF. Risk of severe side effects is especially pronounced in younger male or highly active patients. CRRT and glucocorticoid therapy should be given as soon as possible after diagnosis, while HBO and PTR may be helpful for myositis and neuritis. Patients should be closely monitored for CK levels, myopathic symptoms, and blood lactate levels during telbivudine treatment.
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